{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T22:21:53Z","timestamp":1774563713552,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[1998,9,1]],"date-time":"1998-09-01T00:00:00Z","timestamp":904608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1998,9,1]],"date-time":"1998-09-01T00:00:00Z","timestamp":904608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[1998,9]]},"DOI":"10.1378\/chest.114.3_supplement.237s","type":"journal-article","created":{"date-parts":[[2008,1,22]],"date-time":"2008-01-22T17:31:17Z","timestamp":1201023077000},"page":"237S-241S","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"S","title":["Clinical Insights Into the Pathogenesis of Primary Pulmonary Hypertension"],"prefix":"10.1016","volume":"114","author":[{"given":"Stuart","family":"Rich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1378\/chest.114.3_Supplement.237S_bib1","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1161\/01.CIR.56.5.884","article-title":"Clinical primary pulmonary hypertension: three pathologic types","volume":"56","author":"Edwards","year":"1977","journal-title":"Circulation"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1161\/01.CIR.22.4.535","article-title":"Vasoconstriction and medial hypertrophy in pulmonary hypertension","volume":"22","author":"Wagenvoort","year":"1960","journal-title":"Circulation"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib3","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1161\/01.CIR.42.6.1163","article-title":"Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 clinically diagnosed cases","volume":"42","author":"Wagenvoort","year":"1970","journal-title":"Circulation"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib4","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1161\/01.CIR.80.5.1198","article-title":"Histopathology of primary pulmonary hypertension: a qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute Primary Pulmonary Hypertension Registry","volume":"80","author":"Pietra","year":"1989","journal-title":"Circulation"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/hrt.20.4.557","article-title":"Pulmonary hypertension with special reference to the vasoconstrictive factor","volume":"20","author":"Wood","year":"1958","journal-title":"Br Heart J"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1378\/chest.89.4.497","article-title":"Pharmacologically-induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension","volume":"89","author":"Barst","year":"1986","journal-title":"Chest"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib7","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1164\/ajrccm.151.2.7842196","article-title":"Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: a dose-response study and comparison with prostacyclin","volume":"151","author":"Sitbon","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib8","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1161\/01.CIR.80.5.1207","article-title":"Primary pulmonary hypertension: vascular structure, morphometry, and responsiveness to vasodilator agents","volume":"80","author":"Palevsky","year":"1989","journal-title":"Circulation"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0026-2862(89)90017-4","article-title":"Progressive inflammatory and skeletal changes in the pulmonary vasculature of monocrotaline-treated rats","volume":"38","author":"Wilson","year":"1989","journal-title":"Microvasc Res"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib10","first-page":"H1584","article-title":"Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension","volume":"255","author":"Rosenberg","year":"1988","journal-title":"Am J Physiol"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib11","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/327524a0","article-title":"Nitric oxide release accounts for the biologic activity of endothelium-derived relaxing factor","volume":"327","author":"Palmer","year":"1987","journal-title":"Nature"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib12","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM199507273330403","article-title":"Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension","volume":"333","author":"Giaid","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib13","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1161\/01.CIR.87.2.440","article-title":"Impairment of endothelium dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics","volume":"87","author":"Celermajer","year":"1993","journal-title":"Circulation"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib14","first-page":"342","article-title":"The case for treatment of selected patients with primary pulmonary hypertension","volume":"134","author":"Reeves","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/01.CIR.76.1.135","article-title":"High-dose calcium channel blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy","volume":"76","author":"Rich","year":"1997","journal-title":"Circulation"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension","volume":"327","author":"Rich","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib17","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/0735-1097(92)90295-X","article-title":"Comparison on the effects of adenosine and nifedipine in pulmonary hypertension","volume":"19","author":"Schrader","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib18","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0735-1097(91)90556-O","article-title":"High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing","volume":"18","author":"Rich","year":"1991","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib19","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0735-1097(84)80048-0","article-title":"Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative vascular disease","volume":"4","author":"Packer","year":"1984","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib20","series-title":"Primary pulmonary hypertension","first-page":"83","article-title":"Pathophysiology of primary pulmonary hypertension from physiology to molecular mechanisms","author":"Voelkel","year":"1997"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0024-3205(93)90131-L","article-title":"Endothelin peptides: biological actions and pathophysiological significance in the lung","volume":"S2","author":"Filep","year":"1993","journal-title":"Life Sci"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib22","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1161\/01.CIR.84.6.2280","article-title":"Plasma endothelin concentration in patients with pulmonary hypertension associated with congenital heart defects: evidence for increased production of endothelin in the pulmonary circulation","volume":"84","author":"Yoshibayashi","year":"1991","journal-title":"Circulation"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib23","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/0735-1097(95)00399-1","article-title":"Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamics and endothelin levels","volume":"26","author":"Nootens","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib24","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib25","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","article-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension","volume":"327","author":"Christman","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib26","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/273767a0","article-title":"Prostacyclin is a circulating hormone","volume":"273","author":"Moncada","year":"1978","journal-title":"Nature"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib27","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","article-title":"Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol)","volume":"112","author":"Rubin","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib28","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous prostacyclin versus conventional therapy in primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib29","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0735-1097(97)00187-3","article-title":"Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion","volume":"30","author":"Shapiro","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib30","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/0003-4819-121-6-199409150-00003","article-title":"Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin","volume":"121","author":"Barst","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib31","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1056\/NEJM199801293380501","article-title":"Reduction in pulmonary vascular resistance with long-term prostacyclin therapy in primary pulmonary hypertension","volume":"338","author":"McLaughlin","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/01.CIR.67.1.155","article-title":"Captropril in primary pulmonary hypertension","volume":"67","author":"Leier","year":"1983","journal-title":"Circulation"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib34","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1164\/ajrccm.154.4.8887612","article-title":"Angiotensin converting enzyme expression in primary pulmonary hypertension","volume":"154","author":"Schuster","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib35","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/01.CIR.82.3.841","article-title":"Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension","volume":"82","author":"Eisenberg","year":"1990","journal-title":"Circulation"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib36","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.CIR.70.4.580","article-title":"Primary pulmonary hypertension: natural history and the importance of thrombosis","volume":"70","author":"Fuster","year":"1984","journal-title":"Circulation"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib37","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0735-1097(86)80277-7","article-title":"Regression in thromboembolic type of primary pulmonary hypertension during 2\u00bd years of antithrombotic therapy","volume":"7","author":"Cohen","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib38","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1161\/01.CIR.91.3.741","article-title":"Do patients with primary pulmonary hypertension develop extensive central thrombi?","volume":"91","author":"Moser","year":"1995","journal-title":"Circulation"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib39","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1378\/chest.104.1.236","article-title":"ACCP Consensus Statement: primary pulmonary hypertension","volume":"104","author":"Rubin","year":"1993","journal-title":"Chest"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib40","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1164\/ajrccm\/138.4.952","article-title":"Heterogeneity of pathologic lesions in familial primary pulmonary hypertension","volume":"138","author":"Loyd","year":"1988","journal-title":"Am Rev Respir Dis"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib41","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1378\/chest.89.5.694","article-title":"Pulmonary vascular disease in secundum atrial septal defect with pulmonary hypertension","volume":"89","author":"Yamaki","year":"1986","journal-title":"Chest"},{"key":"10.1378\/chest.114.3_Supplement.237S_bib42","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1378\/chest.95.2.325","article-title":"Pulmonary hypertension due to toxic oil syndrome: a clinicopathologic study","volume":"95","author":"Gomez-Sanchez","year":"1989","journal-title":"Chest"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215477955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215477955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T07:19:40Z","timestamp":1757920780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369215477955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,9]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1998,9]]}},"alternative-id":["S0012369215477955"],"URL":"https:\/\/doi.org\/10.1378\/chest.114.3_supplement.237s","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[1998,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Insights Into the Pathogenesis of Primary Pulmonary Hypertension","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1378\/chest.114.3_Supplement.237S","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1998 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}